Even as government and private health plans push to restrain spending on medicines, the prices of brand name prescriptions are climbing rapidly, reaching the steepest rate of the decade last year.March 16, 2011, 11:02 AM
A war over Lipitor pricing could impact your pocketbook whether or not you take the best-selling cholesterol-lowering pill.January 7, 2011, 5:18 PM
There are coupons or subsidy cards to reduce copays for about half of the top 100 brand name drugs sold in this country, according to a recent report from health analyst Richard Evans at Sector & Sovereign Research.May 19, 2010, 6:00 AM
If you want to understand why Pfizer is closing eight manufacturing plants and laying off 6,000 workers over the next five years, its plant at Loughbeg in County Cork, Ireland, would be a good place to start.
Richard Evans guides institutional investors through his Healthcare research at Bloomberg World Headquarters in May of this year. The symposium was hosted by Bloomberg Tradebook and materials are available upon request.
Since November, one experienced industry analyst has been saying health care reform is “simply over.” What does he think now?January 20, 2010, 8:53 AM
The Kennedy seat in the Senate is gone. With its loss, Democrats’ hopes for passing an overhaul of the nation’s health system have faded, too.
Arguing that the political winds are shifting away from the support necessary for an overhaul, one Wall Street analyst is now predicting Congress will not pass any significant health care legislation anytime soon.
In a report sent to investors earlier this week, a Wall Street analyst, Richard Evans, concludes that the health insurance industry should probably not worry much about the prospect of a government-run health plan — at least not as it now is taking shape in Congress.
Some have criticized the Baucus health care proposal as punitive because it would fine people who did not sign up for health insurance. But a Wall Street health care analyst says the fines are too low.